Yang Liu Email & Phone Number

Boston, Massachusetts, United States

Mirati was acquired by BMS in Jan 2024.Clinical Development – Oncology (NSCLC and other solid tumors, e.g., CRC, urothelial carcinoma, renal cell carcinoma).• Worked with cross-functional teams to successfully achieve database lock for final analysis for two global phase 3 studies: 1) SAPPHIRE (Sitravatinib in combination with Nivolumab versus Docetaxel), and 2) KRYSTAL-12 (Adagrasib versus Docetaxel) in patients with previously treated NSCLC.• Acting Medical Monitor for a phase 2… Show more Mirati was acquired by BMS in Jan 2024.Clinical Development – Oncology (NSCLC and other solid tumors, e.g., CRC, urothelial carcinoma, renal cell carcinoma).• Worked with cross-functional teams to successfully achieve database lock for final analysis for two global phase 3 studies: 1) SAPPHIRE (Sitravatinib in combination with Nivolumab versus Docetaxel), and 2) KRYSTAL-12 (Adagrasib versus Docetaxel) in patients with previously treated NSCLC.• Acting Medical Monitor for a phase 2 study.• Contributed to Adagrasib sNDA for full approval.• Contributed to clinical trial protocol development and other study documents review, e.g., ICF, CSR, IB, eCRF, CCGs, TFLs. Show less

Greater Boston

Clinical Development - Hematological malignancies including lymphoma and leukemia (phases I, II and III)• Performed medical review of patient profiles, data listings/TFLs, and patient monitoring• Contributed to clinical trial protocol development (writing, review and amendment) and execution• Supported development of clinical study documents, e.g., Development Safety Update Report, Period Benefit-Risk Evaluation Report, Independent Data Monitoring Committee Charter, Informed… Show more Clinical Development - Hematological malignancies including lymphoma and leukemia (phases I, II and III)• Performed medical review of patient profiles, data listings/TFLs, and patient monitoring• Contributed to clinical trial protocol development (writing, review and amendment) and execution• Supported development of clinical study documents, e.g., Development Safety Update Report, Period Benefit-Risk Evaluation Report, Independent Data Monitoring Committee Charter, Informed Consent Forms. Show less

Great Boston Area, Massachusetts, United States

Clinical Development - Solid tumors including glioblastoma and melanoma (phases I and II)• Contributed to the clinical trial protocol development and execution• Monitored patient data in EDC• Supported clinical study documents and regulatory submission, e.g., Development Safety Update Report, Clinical Study Report, Investigator Brochure, Data Safety Monitoring Board, orphan drugapplication, informed consent forms, medical monitoring plan• Supported clinical… Show more Clinical Development - Solid tumors including glioblastoma and melanoma (phases I and II)• Contributed to the clinical trial protocol development and execution• Monitored patient data in EDC• Supported clinical study documents and regulatory submission, e.g., Development Safety Update Report, Clinical Study Report, Investigator Brochure, Data Safety Monitoring Board, orphan drugapplication, informed consent forms, medical monitoring plan• Supported clinical development/disease strategy planning including data analysis and literature review Show less

Rochester, New York Area

Conducted clinical research and investigated novel therapeutic targets for brain cancer including primary brain cancer and brain metastasis from other cancers. • Collaborated with a pharmaceutical company to design/implement preclinical study of drug targeting brain cancer.• Identified barriers to clinical trial participation (phase 1-3), characterized strategy to maximize clinical trial outcomes.• Collaborated with industry and academia to carry out clinical research (phase 4) for… Show more Conducted clinical research and investigated novel therapeutic targets for brain cancer including primary brain cancer and brain metastasis from other cancers. • Collaborated with a pharmaceutical company to design/implement preclinical study of drug targeting brain cancer.• Identified barriers to clinical trial participation (phase 1-3), characterized strategy to maximize clinical trial outcomes.• Collaborated with industry and academia to carry out clinical research (phase 4) for brain cancer.• Supervised/trained lab technicians and students. Show less

Greater Pittsburgh Area

Managed study and played a critical role in investigating and identifying biomarkers for early detection of lung cancer. Demonstrated that multiple genes were methylated in lung tumor, and furthermore, that specific gene methylation can be detected in sputum from high-risk population, suggesting potential clinical implications for diagnosis of lung cancer.

Mba, Health Sciences Management, Finance

Ph.D

Md